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1101-42 TAXUS IV: Results From the Intravascular Ultrasound 
Substudy
Neil J. Weissman, Stephen Ellis, Mark Turco, Joel Greenberg, James Tift Mann, Michael 
Kutcher, S. Chiu Wong, Charles O'Shaughnessy, Mary Russell, Gregg W. Stone, 
Washington Hospital Center, Washington, DC
Background: The TAXUS IV multicenter, randomized, double-blind clinical trial demon-
strated that the TAXUS stent decreases clinical events and angiographic restenosis.
Methods: In order to enhanced our understanding of the relative efficacy and safety of
the TAXUS stent, a pre-specified IVUS substudy was conducted at 27 sites in 268
patients. Consecutive patients enrolled into the TAXUS IV study at these sites were man-
dated to use IVUS at implantation and follow-up. Standard IVUS imaging methods (IC
nitroglycerine, motorized pullback) and core lab volumetric analysis was performed
throughout the stent and edges.
Results: Of the 199 patients returning for a 9-month follow-up IVUS, 178 (90%) were
technically adequate for subsequent analysis (87 control, 91 TAXUS). Baseline IVUS vol-
umes (vessel, stent and lumen volume) at implantation were similar in each group. Follow
up volumes are below (table): 
The neointima reduction was uniform throughout the stent. In addition, there was no dif-
ference in the lumen loss at the margins beyond the stent edges except for a reduction of
the lumen loss for the first mm at the distal edge in the TAXUS group (p=0.004). Late
incomplete stent apposition only occurred in 2 control patients and 1 TAXUS patient
(p=0.62).
Conclusion: The TAXUS stent decreased neointima volume uniformly throughout the
stent without any negative edge effects and without any increase in late incomplete appo-
sition.
1101-43 Longitudinal Vessel Remodeling Pattern Following 
Sirolimus-Eluting Stent Implantation: Analysis of Vessel 
Integrity Throughout Target Segment
Hideaki Kaneda, Junya Ako, Yasuhiro Honda, Ryota Sakurai, Mitsuyasu Terashima, 
Shinjo Sonoda, Yoshihisa Shimada, Yoshihiro Morino, Paul G. Yock, Martin B. Leon, 
Jeffrey W. Moses, Peter J. Fitzgerald, The SIRIUS Investigators, Stanford University, 
Stanford, CA, Lenox Hill Hospital, New York, NY
Background: Previous studies of drug-eluting stents have shown asymmetric effect on
neointimal hyperplasia (i.e., greater neointima at proximal vs distal stent edge). These
results may be caused by longitudinally asymmetric drug diffusion, delivery technique
and/or margin injury. Our study objective was to assess whether vessel remodeling fol-
lowing sirolimus-eluting stent (SES) implantation is longitudinally asymmetric.
Methods: Thirty-six patients who underwent single 18 mm stent implantation (23 SES
and 13 control Bx VELOCITY) and serial (baseline and 8 month follow-up) three-dimen-
sional IVUS were enrolled in this study from the overall SIRIUS population. Five 2 mm-
subsegments were chosen from each patient: proximal/ distal adjacent or instent edge
segments within 2 mm from the stent edge and at the center of stent. Vessel (inside the
external elastic membrane) and plaque plus neointima (vessel- lumen) volume were cal-
culated and divided by length to create an average area. Serial change was calculated as
follow up - baseline measurements.
Results: The amount and pattern of plaque plus neointima area change was significantly
different between SES and control (Left Fig.). However, there wase no significant differ-
ence in remodeling between the two treatment groups nor among different segments
using two-way ANOVA (Right Fig.).
Conclusion: There was no detectable difference in the remodeling pattern of SES and
control stents, despite significant difference in plaque plus neointima distribution. 
1101-44 Effect of Everolimus-Eluting Stents in Preventing 
Neointimal Hyperplasia: An Intravascular Ultrasound 
Analysis From the FUTURE II Trial
Shinjo Sonoda, Eberhard Grube, Yoshihisa Shimada, Ali H.M Hassan, Yasuhiro Honda, 
Paul G. Yock, Charles Chan, Hidehiko Honda, Saibal Kar, Karl E. Hauptmann, Hans 
Storger, Alexandra J. Lansky, Peter J. Fitzgerald, The FUTURE II Investigators, Stanford 
University Medical Center, Stanford, CA, Heart Center Siegburg, Siegburg, Germany
Background: FUTURE II is a prospective, randomized, multicenter, double-blind trial
comparing everolimus-eluting stents (EES), coated with a bioabsorbable polymer, to con-
ventional metallic stents (MS). This study includes a more restenosis-prone lesion subset
than FUTURE I. The purpose of this IVUS substudy was to investigate the antiprolifera-
tive efficacy of EES compared to MS in this more complex lesion subset.
Methods and Results: To date, serial 3-D IVUS analyses (baseline and 6 months follow-
up) are available in 41 patients. To adjust volume data to different stent lengths, volume
index was calculated as volume divided by stent length (VVI: vessel volume index, SVI:
stent volume index, LVI: lumen volume index). Percent neointimal volume (%NV) was
defined as neointimal volume divided by stent volume. At baseline, EES achieved stent
expansion similar to MS. VVI within the stented segment and SVI were not different
between groups either at baseline or at follow-up. LVI was also comparable between
groups at baseline. However, LVI at follow-up was significantly larger in EES than in MS
(P<0.05) and %NV was significantly lower in EES than in MS (P<0.0001, 95% reduction).
There was no evidence of unhealed dissections or late stent malapposition in either
group.
Conclusion: Everolimus-eluting stents demonstrated marked antiproliferative efficacy
compared to MS with no evidence of IVUS-detected adverse effects. 
1101-45 Contribution of Stent Underexpansion to Target Lesion 
Revascularization After Sirolimus-Eluting Stenting for 
In-Stent Restenosis
Kenichi Fujii, Yoshio Kobayashi, Gary S. Mintz, Hideo Takebayashi, Takenori Yasuda, 
David Jacoboff, Issam Moussa, Roxana Mehran, George Dangas, Alexandra Lansky, 
Edward Kreps, Michael Collins, Gregg W. Stone, Martin B. Leon, Jeffrey W. Moses, 
Cardiovascular Research Foundation, New York, NY
Background: Sirolimus-eluting stents (SES) strongly suppresses neointimal hyperplasia
and prevents target lesion revascularization (TLR) in de novo lesions. However, the effi-
cacy of SES in the treatment of in-stent restenosis (ISR) is less certain. Minimum stent
area (MSA) after stenting is a predictor of TLR. We investigated the relationship between
stent underexpansion and TLR after SES treatment of ISR.
Methods: In 40 ISR lesions treated with SES, 3-D intravascular ultrasound (IVUS) analy-
sis was performed. Stent and reference segments were measured every 1mm, and vol-
umes were calculated using Simpson’s rule. Stent underexpansion was MSA <5.0 mm2
and <80% of the average reference lumen. A residual edge lesion was stent edge plaque
burden (plaque/external elastic membrane [EEM]) >50%. Eight lesions required TLR; 32
did not.
Results: Stent underexpansion was observed in 6 TLR lesions (75%) and 11 non-TLR
lesions (34%, p=0.04). A gap between stents was detected in 3 TLR lesions (38%) and 1
non-TLR lesion (3%, p=0.01). Multivariate analysis identified stent underexpansion as
the only independent predictor of TLR (p=0.04).
Conclusions: SES fail in 25% of patients after treatment of ISR. IVUS analysis shows
that stent underexpansion, in particular, is associated with failure after SES implantation
to treat ISR.
CONTROL TAXUS p-value
Vessel vol (mm3) 286 288 0.92
Stent vol (mm3) 147 150 0.66
Lumen vol (mm3) 106 131 0.001
Neointima vol (mm3) 41 18 <0.001
% vol obstruction 29.4% 12.2% <0.001
EES MS P-value
Baseline
VVI, mm3/mm 15.6 ± 5.8 16.6 ± 4.7 0.53
SVI, mm3/mm 7.5 ± 2.2 7.9 ± 2.2 0.60
6 months follow-up
VVI, mm3/mm 15.7 ± 5.7 17.0 ± 4.9 0.46
SVI, mm3/mm 7.7 ± 2.1 7.8 ± 2.2 0.82
LVI, mm3/mm 7.6 ± 2.1 6.2 ± 2.3 < 0.05
%NV, % 1.2 ±1.9 22.0 ±16.0 <0.0001
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1101-46 First Human Experience With the ABT-578 Eluting 
Phosphorylcholine Polymer Stent: A Serial Volumetric 
Intravascular Ultrasound Analysis From the PREFER 
Trial
Ryota Sakurai, Yoichiro Hongo, John Ormiston, Robert J. Whitbourn, Ian Meredith, 
Yasuhiro Honda, Paul G. Yock, Peter J. Fitzgerald, The PREFER Trial Investigators, 
Stanford University, Stanford, CA, Green Lane Hospital, Auckland, New Zealand
Background: ABT-578, an analog of rapamycin, is an anti-proliferative agent with prom-
ising preclinical study results. PREFER is a multicenter, non-randomized, single-arm,
feasibility trial of the ABT-578 eluting phosphorylcholine-coated BiodivYsio® (Abbott Vas-
cular Devices, Redwood City, CA) stent which enrolled 11 cases with de novo human cor-
onary lesions. The aim of this substudy was to evaluate the impact of this new drug-
eluting stent on both stented segment and stent edges.
Methods: Serial 3-D IVUS analysis (baseline and 3-month follow-up) was available in 9
out of 11 patients (one case was excluded due to low IVUS image quality; the other due
to additional dilatation with a non-study stent). Minimum lumen area (LA) and mean
areas for lumen, plaque (PA), stent (SA), vessel (VA) and neointima (NIA) were mea-
sured over the stented and the stent edge (both 5 mm proximal and distal adjacent to the
stent) segments.
Results: At baseline, neither significant plaque protrusion / thrombus nor edge dissec-
tion was detected. At follow-up, no late incomplete stent apposition was observed. Mean
NIA was 0.17 ± 0.32 mm2, and %NIA (100*mean NIA/mean SA) was 2.11 ± 3.96%.
Table shows serial changes in quantitative IVUS parameters.
Conclusion: Preliminary analysis of the initial human experience with the ABT-578 elut-
ing phosphorylcholine-coated stent showed no apparent adverse vessel response. The
amount of neointimal proliferation was minimum. Further studies will be needed to con-
firm these favorable observations. 
1101-63 Impact of Preinterventional Lesion Calcification on 
Neointimal Hyperplasia Following Sirolimus-Eluting 
Stent Implantation: An Intravascular Ultrasound 
Analysis
Hideaki Kaneda, Tomomi Koizumi, Junya Ako, Yasuhiro Honda, Mitsuyasu Terashima, 
Yoshihisa Shimada, Yoshihiro Morino, Paul G. Yock, Martin B. Leon, Jeffrey W. Moses, 
Peter J. Fitzgerald, The SIRIUS Investigators, Stanford University, Stanford, CA, Lenox 
Hill Hospital, New York, NY
Background: Although the negative impact of lesion calcification on stent expansion is
well known, the effect of calcification on neointimal hyperplasia (IH) following sirolimus-
eluting stent (SES) implantation is not well characterized.
Methods: Eighty-two patients who underwent SES (n=45) or bare metal stent (n=37)
implantation and preinterventional IVUS were enrolled in this substudy from the overall
SIRIUS population. Lesions were divided into calcified (defined as calcific deposits at
minimum lumen area cross section), or non-calcified. Stent, lumen, IH (stent-lumen) area
were measured at baseline and 8 month follow-up.
Results: Overall, acute lumen area gain tended to be less in calcified lesion (5.19±2.38
vs. 6.06±2.43mm2, P=0.13), resulting in smaller stent area (7.90±2.60 vs.8.70±2.56mm2,
P=0.19). There was a significant interaction between calcification and stent type on IH
suppression (Figure). However, multiple logistic regression analysis including stent type,
stent area at baseline, and plaque type showed that stent type was the only predictor for
target lesion revascularization or binary angiographic restenosis.
Conclusion: The treatment effect between sirolimus and control in reducing restenosis
remained constant, irrespective of lesion characteristics. Despite less optimal acute
results in calcified lesions, SES suppressed IH effectively. 
1101-64 Six-Month Intracoronary Ultrasound Findings Following 
Sirolimus-Eluting Stents for the Treatment of 
Restenosis-Prone Coronary Lesions
José Suárez de Lezo, Alfonso Medina, Miguel Romero, Manuel Pan, José Segura, 
Antonio Delgado, Djordje Pavlovic, Isabel Ureña, Enrique Hernández, Juan Herrador, 
Federico Segura, Francisco Melián, Reina Sofía Hospital, Córdoba, Spain, Dr. Negrín 
Hospital, Las Palmas de Gran Canaria, Spain
Background: Drug-eluting stents are promising. However, follow-up information is still
limited. Intravascular ultrasound (IVUS) is a unique tool is evaluating in situ late results.
Methods: We describe the follow-up IVUS findings obtained from 102 patients with coro-
nary lesions prone to restenosis who had been treated with sirolimus-eluting stents
(SES). Lesions were considered at risk for restenosis because of the following reasons:
in-stent restenosis, major bifurcation lesion, long-diffuse stenosis, or chronic total occlu-
sion. Sixty-two patients had more than 1 risk condition for restenosis. The mean age was
60±10 years. All patients had six-month angiographic and IVUS evaluation. Motorized
IVUS pull-back study of the treated segment was always performed. Proximal and distal
references were interrogated at 1 cm from the stent borders. Intrastent IVUS-measure-
ments were also performed. Results: Qualitatively, we observed focal non-stent apposi-
tion in 11 patients and a bulge or minor aneurysm formation in 2. Eleven patients (11%)
showed focal restenosis. In the remaining 91 patients, the stent was covered with a fine
lining. In addition, the intima was thicker at the edges showing compensatory vessel
enlargement. The table summarizes the quantitative results.
Conclusion: These findings show that adequate healing of restenosis-prone lesions
occurs in most patients. However, focal restenosis may develop. A favorable remodeling
is observed at the edges.
1101-65 Predictors of Edge Stenosis Following Sirolimus-
Eluting Stent Deployment: A Quantitative Intravascular 
Ultrasound Analysis From the SIRIUS Trial
Ryota Sakurai, Junya Ako, Shinjo Sonoda, Hideaki Kaneda, Yoshihiro Morino, Mitsuyasu 
Terashima, Ali Hassan, Paul G. Yock, Martin B. Leon, Jeffrey W. Moses, Peter J. 
Fitzgerald, Yasuhiro Honda, Stanford University, Stanford, CA
Background: While sirolimus-eluting stents (SES) have substantially reduced instent
restenosis, less efficacy at stent edges has been reported in the SIRIUS trial, a multi-
center, randomized, prospective clinical trial comparing the sirolimus-eluting Bx VELOCI-
TYTM stent to bare metal stents.
Methods: Angiographic and IVUS data were obtained from SIRIUS. To investigate possi-
ble determinants of peri-stent edge stenosis (defined as diameter stenosis greater than
50% either proximal or distal to the stent) at follow-up, baseline IVUS parameters were
analyzed in 172 edges of 92 SES.
Results: Of these, 6 edges in 6 SES had edge stenosis at 8-month follow-up. Quantita-
tive IVUS results are shown in the table.
Conclusion: The IVUS measurements of maximum stent area (SA) and edge SA com-
pared to reference suggest that overexpansion (not detected by angio balloon / artery
TLR (n=8) No TLR (n=32)
Radiation failure (%) 71 54
Lesion length (mm) 41.4±33.1 25.8±14.5
Number of stents 2.8±1.9 1.6±1.0
Residual edge lesion (%) 25 19
Reference EEM area (mm2) 9.86±6.30 9.47±4.60
Reference lumen area (mm2) 7.31±4.14 6.54±3.44
Minimum stent area (mm2) 4.32±1.98 4.71±1.68
Stente
d
Segme
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Edge Distal Edge
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P-
Value
Baseli
ne
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-Up
P-
Value
Basel
ine
Follow
-Up
P-
Value
Minimum 
LA(mm2)
6.20 6.09 NS 6.42 6.83 NS 6.48 5.96 NS
Mean LA 
(mm2)
7.34 6.95 NS 8.35 8.40 NS 7.90 7.63 NS
Mean PA 
(mm2)
7.41 7.30 NS 6.30 6.06 NS 5.07 4.97 NS
Mean SA 
(mm2)
7.34 7.12 NS — — — — — —
Mean VA 
(mm2)
14.75 14.42 NS 14.65 14.46 NS 12.97 12.60 NS
Intimal 
thickening 
(mm)
Intimal 
area 
(mm2)
Lumen 
area 
(mm2)
Stent 
area 
(mm2)
External elastic 
laminae (mm2)
Proximal 
reference
0.5±0.2 6±3 11±5 -- 19±7
Proximal edge 0.8±0.3 8±4 9±4 -- 20±7
Maximal stent 
diameter
-- 0.8±0.9 6.9±2.2 7.7±2.5 19±5
Minimal lume
n diameter
0.2±0.2 1.0±1.4 4.7±2 6±3 17±6
Distal edge 0.6±0.3 5±2 7±4 -- 14±6
Distal 
reference
0.3±0.2 5±3 7±3 -- 13±6
